Australia to revise device evaluation fees:
This article was originally published in Clinica
Executive Summary
A revised schedule of premarket evaluation fees is to be introduced by the Australian Therapeutic Devices Branch (TDB) during 1995. The fees will be established according to the level of equivalence to a previously evaluated and currently registered device. The greater the equivalence, the lower the fee, according to the Australian Therapeutic Device Bulletin. It will therefore be vital for companies to submit properly developed tables of equivalence in support of product applications, says the TDB. In the case of applications which are received concurrently and which are capable of simultaneous evaluation, the fee charged will be one-third of the normal fee in each category for each of the applications apart from the first.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.